Bo Ma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Bo Ma has a total of 174 co-authors. Here are the top co-authors by number of shared publications:
- Qi Zhang
School of Pharmaceutical Sciences, Nanjing Tech University, Nanjing 211816, China
25 shared publications Jiaqi Li
School of Pharmaceutical Sciences, Nanjing Tech University, Nanjing, 211816, People's Republic of China
17 shared publicationsZhewen Deng
School of Pharmaceutical Sciences, Nanjing Tech University, Nanjing, 211816, People's Republic of China
14 shared publicationsChaoxing Ren
School of Pharmaceutical Sciences, Nanjing Tech University, Nanjing 211816, PR China
8 shared publicationsXiaowen Bao
School of Pharmaceutical Sciences, Nanjing Tech University, Nanjing, 210009, People's Republic of China
8 shared publicationsBeiting Ma
School of Pharmaceutical Sciences, Nanjing Tech University, Nanjing 211816, PR China
6 shared publications
Latest Publications
- Open Access
- 12 November 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (22) , 10164
Structure-Dependent Mechanistic Divergence in Male Reproductive Toxicity Between Bisphenol A and Its Analog Bisphenol S: Integration of Network Toxicology and Molecular Docking
Bisphenol A (BPA), a widespread endocrine-disrupting chemical, has been associated with male reproductive health, yet its structural analog bisphenol S (BPS), selected as a primary alternative, may also pose similar risks. Their comparative reproductive toxic mechanisms remain poorly defined. By integrating network toxicology and molecular docking, we predicted and compared BPA- and BPS-related target and pathway profiles in male reproductive toxicity, and identified candidate hub genes potentially dysregulated in testicular pathology using public datasets. Both chemicals shared ESR1 and TP53 as overlapping targets, and enrichment analysis showed that both were enriched in ESR1/AR signaling and endocrine resistance pathways. BPA was preferentially linked to impairment of immune-barrier function with AKT1, TGFB1, TLR4, and STAT3, whereas BPS mapped to metabolic-oxidative stress processes via MDM2, EGFR, and GSTP1. Immune infiltration analysis linked BPA-related genes inversely to NK cell abundance. Transcription factor analysis identified MYCN and PGR as hub nodes with distinct downstream networks. Molecular docking predicted generally favorable binding of both chemicals to key targets, with target-dependent differences in predicted affinity. These in silico results suggest that BPA and BPS may affect male reproductive health through partly distinct mechanisms, with BPA more closely associated with immune-related pathways and BPS with metabolic-oxidative stress pathways.
- 12 November 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (22) , 10164
Open AccessStructure-Dependent Mechanistic Divergence in Male Reproductive Toxicity Between Bisphenol A and Its Analog Bisphenol S: Integration of Network Toxicology and Molecular Docking
Bisphenol A (BPA), a widespread endocrine-disrupting chemical, has been associated with male reproductive health, yet its structural analog bisphenol S (BPS), selected as a primary alternative, may also pose similar risks. Their comparative reproductive toxic mechanisms remain poorly defined. By integrating network toxicology and molecular docking, we predicted and compared BPA- and BPS-related target and pathway profiles in male reproductive toxicity, and identified candidate hub genes potentially dysregulated in testicular pathology using public datasets. Both chemicals shared ESR1 and TP53 as overlapping targets, and enrichment analysis showed that both were enriched in ESR1/AR signaling and endocrine resistance pathways. BPA was preferentially linked to impairment of immune-barrier function with AKT1, TGFB1, TLR4, and STAT3, whereas BPS mapped to metabolic-oxidative stress processes via MDM2, EGFR, and GSTP1. Immune infiltration analysis linked BPA-related genes inversely to NK cell abundance. Transcription factor analysis identified MYCN and PGR as hub nodes with distinct downstream networks. Molecular docking predicted generally favorable binding of both chemicals to key targets, with target-dependent differences in predicted affinity. These in silico results suggest that BPA and BPS may affect male reproductive health through partly distinct mechanisms, with BPA more closely associated with immune-related pathways and BPS with metabolic-oxidative stress pathways.
- Open Access
- 29 July 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (8) , 931
Targeted Prostatic Delivery of Levofloxacin via a Novel Vas-Deferens Injection Device: A Pharmacokinetic Study in Rats
Objective: Current pharmacological treatments for prostate diseases are limited by poor drug penetration into the prostate and systemic adverse effects. This study evaluated whether a novel vas-deferens injection device could improve targeted delivery of levofloxacin to the prostate. Methods: Healthy adult male Sprague–Dawley rats received a single dose of levofloxacin by either intravenous administration (IV) or trans-vas-deferens administration using a novel disposable device (VS). Plasma and prostate samples were collected from 0.5 to 24 h and analyzed by LC-MS/MS. Iodixanol micro-CT imaging was used to visualize the local delivery pathway. Pharmacokinetic evaluation included observed composite-profile Cmax/Tmax, AUC0-24, and fT. Time-dependent tissue selectivity was evaluated through partial AUC analyses, prostate-to-plasma exposure ratios, and pointwise concentration ratios. A bioequivalence-style framework was applied to compare relative exposure parameters using geometric mean ratios (GMRs) with the 80.00–125.00% reference interval. Exploratory PK/PD evaluation combined literature-derived free-drug fractions (fut_plasma = 0.55, fut_prostate = 0.080) to estimate fAUC/MIC against representative uropathogens, supplemented by Monte Carlo simulation (n = 5000) to estimate probability of target attainment (PTA) at an fAUC/MIC ≥ 30 threshold. Results: Imaging confirmed selective distribution within the reproductive tract after vas-deferens delivery. In plasma, VS substantially reduced systemic exposure compared with IV: Cmax was 4.74 μg/mL (VS) versus 10.72 μg/mL (IV), and AUC0-24 was 15.47 versus 28.59 μg·h/mL. In the prostate, VS maintained comparable or numerically higher exposure: Cmax was 61.96 μg/g (VS) versus 52.02 μg/g (IV), and AUC0-24 was 235.77 versus 208.77 μg·h/g. The tissue distribution factor fT was substantially elevated in VS (2.26; 95% CI: 1.58–3.19) compared with IV (1.06; 95% CI: 0.89–1.30). Bioequivalence-style analysis demonstrated that plasma GMRs for AUC0-24 and Cmax fell well below 80%, confirming reduced systemic burden, while prostate GMRs were maintained, and the prostate-to-plasma AUC ratio GMR was increased. Time-dependent partial AUC analyses revealed that VS significantly elevated the prostate-to-plasma exposure ratio. PK/PD evaluation showed that at 24 h, prostate fAUC/MIC against Enterobacteriaceae (MIC = 0.5 μg/mL) was 37.7 (VS) versus 33.4 (IV), with corresponding PTA values of 97% and 94%, while plasma fAUC/MIC remained substantially lower in the VS group. Conclusions: Trans-vas-deferens administration of levofloxacin via a novel injection device effectively reduced systemic drug exposure while maintaining or enhancing prostate tissue concentrations, thereby widening the therapeutic window and reducing systemic drug exposure.
- 29 July 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (8) , 931
Open AccessTargeted Prostatic Delivery of Levofloxacin via a Novel Vas-Deferens Injection Device: A Pharmacokinetic Study in Rats
Objective: Current pharmacological treatments for prostate diseases are limited by poor drug penetration into the prostate and systemic adverse effects. This study evaluated whether a novel vas-deferens injection device could improve targeted delivery of levofloxacin to the prostate. Methods: Healthy adult male Sprague–Dawley rats received a single dose of levofloxacin by either intravenous administration (IV) or trans-vas-deferens administration using a novel disposable device (VS). Plasma and prostate samples were collected from 0.5 to 24 h and analyzed by LC-MS/MS. Iodixanol micro-CT imaging was used to visualize the local delivery pathway. Pharmacokinetic evaluation included observed composite-profile Cmax/Tmax, AUC0-24, and fT. Time-dependent tissue selectivity was evaluated through partial AUC analyses, prostate-to-plasma exposure ratios, and pointwise concentration ratios. A bioequivalence-style framework was applied to compare relative exposure parameters using geometric mean ratios (GMRs) with the 80.00–125.00% reference interval. Exploratory PK/PD evaluation combined literature-derived free-drug fractions (fut_plasma = 0.55, fut_prostate = 0.080) to estimate fAUC/MIC against representative uropathogens, supplemented by Monte Carlo simulation (n = 5000) to estimate probability of target attainment (PTA) at an fAUC/MIC ≥ 30 threshold. Results: Imaging confirmed selective distribution within the reproductive tract after vas-deferens delivery. In plasma, VS substantially reduced systemic exposure compared with IV: Cmax was 4.74 μg/mL (VS) versus 10.72 μg/mL (IV), and AUC0-24 was 15.47 versus 28.59 μg·h/mL. In the prostate, VS maintained comparable or numerically higher exposure: Cmax was 61.96 μg/g (VS) versus 52.02 μg/g (IV), and AUC0-24 was 235.77 versus 208.77 μg·h/g. The tissue distribution factor fT was substantially elevated in VS (2.26; 95% CI: 1.58–3.19) compared with IV (1.06; 95% CI: 0.89–1.30). Bioequivalence-style analysis demonstrated that plasma GMRs for AUC0-24 and Cmax fell well below 80%, confirming reduced systemic burden, while prostate GMRs were maintained, and the prostate-to-plasma AUC ratio GMR was increased. Time-dependent partial AUC analyses revealed that VS significantly elevated the prostate-to-plasma exposure ratio. PK/PD evaluation showed that at 24 h, prostate fAUC/MIC against Enterobacteriaceae (MIC = 0.5 μg/mL) was 37.7 (VS) versus 33.4 (IV), with corresponding PTA values of 97% and 94%, while plasma fAUC/MIC remained substantially lower in the VS group. Conclusions: Trans-vas-deferens administration of levofloxacin via a novel injection device effectively reduced systemic drug exposure while maintaining or enhancing prostate tissue concentrations, thereby widening the therapeutic window and reducing systemic drug exposure.
- 15 July 2026
- Published by Elsevier in Chemico-Biological Interactions
- Vol. 437, 112255
Pristimerin disrupts blood-testis barrier (BTB) integrity via ferroptosis and apoptosis by the NUR77/ATF3/CHOP pathway
- 15 July 2026
- Published by Elsevier in Chemico-Biological Interactions
- Vol. 437, 112255
Pristimerin disrupts blood-testis barrier (BTB) integrity via ferroptosis and apoptosis by the NUR77/ATF3/CHOP pathway
- 20 June 2026
- Published by Elsevier in Molecular Immunology
- Vol. 196, 133-147
Cordycepin attenuates diabetic nephropathy by dual-pathway activation of TFEB to restore autophagy and ameliorate podocyte injury
- 20 June 2026
- Published by Elsevier in Molecular Immunology
- Vol. 196, 133-147
Cordycepin attenuates diabetic nephropathy by dual-pathway activation of TFEB to restore autophagy and ameliorate podocyte injury
- Open Access
- 25 March 2026
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 24 (1)
Mitochondria in situ releasing corosolic acid enhanced antitumor effects via activating mitophagy in castration-resistant prostate cancer
Corosolic acid (CA) and its derivatives have shown promise as anticancer agents, but their effectiveness against resistant cancer types remains underexplored. Organelle-targeted drug delivery is a promising approach to enhance therapeutic efficacy and reduce side effects. A mitochondria-targeted prodrug, CA-TPP, was synthesized using an esterase-responsive phenolic ester bond, which enables the in situ release of CA within the mitochondria. The therapeutic efficacy of CA-TPP was assessed both in vitro (using DU145 cells) and in vivo. RNA sequencing was employed to investigate the molecular mechanisms, particularly focusing on the PINK1/Parkin-mediated mitophagy pathway. CA-TPP significantly reduced the required treatment dose of CA by 75%, maintaining its anticancer activity. In DU145 cells, CA-TPP induced cell death through the mitochondrial apoptosis pathway. RNA sequencing revealed that CA-TPP activated apoptosis through PINK1/Parkin-mediated mitophagy. Inhibition of mitophagy via PINK1 shRNA alleviated the cytotoxic effects of CA-TPP, confirming the role of mitophagy in its mechanism. Additionally, CA-TPP treatment resulted in elevated ROS production, leading to mitochondrial apoptosis and mitophagy. The CA-TPP prodrug strategy enhances the specificity and anti-tumor effects of corosolic acid, offering a promising approach for targeted cancer therapy. This work opens new possibilities for mitochondria-targeted cancer treatments with reduced drug dosages. This study did not involve clinical trials, and thus trial registration is not applicable. The online version contains supplementary material available at 10.1186/s12967-026-08057-6.
- 25 March 2026
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 24 (1)
Open AccessMitochondria in situ releasing corosolic acid enhanced antitumor effects via activating mitophagy in castration-resistant prostate cancer
Corosolic acid (CA) and its derivatives have shown promise as anticancer agents, but their effectiveness against resistant cancer types remains underexplored. Organelle-targeted drug delivery is a promising approach to enhance therapeutic efficacy and reduce side effects. A mitochondria-targeted prodrug, CA-TPP, was synthesized using an esterase-responsive phenolic ester bond, which enables the in situ release of CA within the mitochondria. The therapeutic efficacy of CA-TPP was assessed both in vitro (using DU145 cells) and in vivo. RNA sequencing was employed to investigate the molecular mechanisms, particularly focusing on the PINK1/Parkin-mediated mitophagy pathway. CA-TPP significantly reduced the required treatment dose of CA by 75%, maintaining its anticancer activity. In DU145 cells, CA-TPP induced cell death through the mitochondrial apoptosis pathway. RNA sequencing revealed that CA-TPP activated apoptosis through PINK1/Parkin-mediated mitophagy. Inhibition of mitophagy via PINK1 shRNA alleviated the cytotoxic effects of CA-TPP, confirming the role of mitophagy in its mechanism. Additionally, CA-TPP treatment resulted in elevated ROS production, leading to mitochondrial apoptosis and mitophagy. The CA-TPP prodrug strategy enhances the specificity and anti-tumor effects of corosolic acid, offering a promising approach for targeted cancer therapy. This work opens new possibilities for mitochondria-targeted cancer treatments with reduced drug dosages. This study did not involve clinical trials, and thus trial registration is not applicable. The online version contains supplementary material available at 10.1186/s12967-026-08057-6.